Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletionLeila Amini, Mohamed Abou‐El‐Enein, Sara Silbert et al.|Nature Reviews Clinical Oncology|2022Cited by 324
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Susan R. Rheingold, Richard Sposto et al.|Leukemia|2018Cited by 209
Secondary solid cancer screening following hematopoietic cell transplantationYoshihiro Inamoto, Navneet S. Majhail, Robert J. Hayashi et al.|Bone Marrow Transplantation|2015Cited by 185
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)Ankit Kansagra, Shahrukh K. Hashmi, Noelle V. Frey et al.|Bone Marrow Transplantation|2019Cited by 119
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular TherapyAnkit Kansagra, Shahrukh K. Hashmi, Noelle V. Frey et al.|Biology of Blood and Marrow Transplantation|2018Cited by 106